Back

Corbus CRB-913 cuts weight 5.0% in Phase 1b obesity trial

Verifying
  • Corbus Pharmaceuticals reported CANYON-1 results for obesity candidate CRB-913.
  • 5.0% was the placebo-adjusted mean weight reduction at the 60 mg dose.
  • Corbus plans to present detailed data at ObesityWeek 2026 and pursue Phase 2 in 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Corbus CRB-913 cuts weight 5.0% in Phase 1b obesity trial - CoinPost Terminal